Merck\'s Keytruda wins FDA approval as combination therapy for kidney cancer

Merck's Keytruda wins FDA approval as combination therapy for kidney cancer

The U.S. Food and Drug Administration has approved Merck & Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.

More From BioPortfolio on "Merck's Keytruda wins FDA approval as combination therapy for kidney cancer"